Literature DB >> 22556022

Oral contraceptives do not appear to affect cystic fibrosis disease severity.

Natalie G Kernan1, Eric W F W Alton, Paul Cullinan, Uta Griesenbach, Diana Bilton.   

Abstract

Several studies suggest that sex may affect cystic fibrosis (CF) disease severity, with females with CF being more severely affected. In this context, it has been suggested that sex hormones may influence the CF phenotype. A large proportion of females with CF regularly use oral contraceptives (OCs), but the effect of their use on disease severity is unclear. Here, we retrospectively assessed the effects of OCs on clinical outcomes in females with CF. Data from 681 females were available, of whom 42% had taken OCs for varying periods of time. We first performed an inter-patient analysis comparing annual change in % predicted forced expiratory volume in 1 s, body mass index and total days of intravenous antibiotic use over a 5-yr study period in 57 females exposed to and 57 females not exposed to OCs. There were no differences between the two groups. We next performed an intra-patient analysis of the same outcomes over a 3-yr period of OC exposure and a 3-yr period of no OC exposure in the same patient (exposure followed by non-exposure, n=27; non-exposure followed by exposure, n=23), but again did not detect any differences in any of the clinical outcomes. Our data suggests that the use of OCs does not affect CF disease severity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22556022     DOI: 10.1183/09031936.00018712

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  6 in total

1.  Relationship Between Estrogen Treatment and Skeletal Health in Women With Cystic Fibrosis.

Authors:  Malinda Wu; Erika L Bettermann; Neha Arora; William R Hunt; Courtney McCracken; Vin Tangpricha
Journal:  Am J Med Sci       Date:  2020-06-06       Impact factor: 2.378

2.  Effects of puberty on cystic fibrosis related pulmonary exacerbations in women versus men.

Authors:  Shelby Sutton; Daniel Rosenbluth; Deepa Raghavan; Jie Zheng; Raksha Jain
Journal:  Pediatr Pulmonol       Date:  2013-03-04

Review 3.  Optimizing sexual and reproductive health across the lifespan in people with cystic fibrosis.

Authors:  Natalie E West; Traci M Kazmerski; Jennifer L Taylor-Cousar; Vin Tangpricha; Kelsie Pearson; Moira L Aitken; Raksha Jain
Journal:  Pediatr Pulmonol       Date:  2021-10-08

Review 4.  Recent advances in understanding and managing cystic fibrosis transmembrane conductance regulator dysfunction.

Authors:  Uta Griesenbach; Eric W F W Alton
Journal:  F1000Prime Rep       Date:  2015-05-27

5.  Brazilian guidelines for the diagnosis and treatment of cystic fibrosis.

Authors:  Rodrigo Abensur Athanazio; Luiz Vicente Ribeiro Ferreira da Silva Filho; Alberto Andrade Vergara; Antônio Fernando Ribeiro; Carlos Antônio Riedi; Elenara da Fonseca Andrade Procianoy; Fabíola Villac Adde; Francisco José Caldeira Reis; José Dirceu Ribeiro; Lídia Alice Torres; Marcelo Bicalho de Fuccio; Matias Epifanio; Mônica de Cássia Firmida; Neiva Damaceno; Norberto Ludwig-Neto; Paulo José Cauduro Maróstica; Samia Zahi Rached; Suzana Fonseca de Oliveira Melo
Journal:  J Bras Pneumol       Date:  2017 May-Jun       Impact factor: 2.624

6.  Use of estrogen supplementation is associated with higher quality of life scores in women with cystic fibrosis.

Authors:  Malinda Wu; Neha Arora; Viranuj Sueblinvong; William R Hunt; Vin Tangpricha
Journal:  J Clin Transl Endocrinol       Date:  2021-12-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.